

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GREEN FRESH BIOTECHNOLOGY COMPANY LIMITED

綠新生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code:1084)

PROFIT WARNING FOR THE YEAR ENDED 31 DECEMBER 2025

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Green Fresh Biotechnology Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

Following a preliminary review of the currently available information which includes, but without limitation to, the unaudited consolidated management accounts of the Group for the year ended 31 December 2025 (“**FY2025**”), the Board wishes to inform the shareholders (the “**Shareholders**”) and the prospective investors of the Company that the Company is expected to record a net profit attributable to owners of the Company (the “**Net Profit**”) of not more than RMB8.0 million for FY2025, as compared to the net profit attributable to owners of the Company of approximately RMB62.2 million for the year ended 31 December 2024 (“**FY2024**”). Such deterioration in the Net Profit was primarily due to the decrease in the price and volume of the Group’s major types of hydrocolloid products which have resulted in the decrease in both revenue and gross profit for FY2025.

The Company is finalising the consolidated final results of the Group for FY2025. Hence, the information disclosed in this announcement only represents a preliminary assessment by the Board and the management of the Group based on the information currently available to the Board which includes, but without limitation to, the unaudited consolidated management accounts of the Group for FY2025 which has not been reviewed by the auditors of the Company or the audit committee of the Board. The consolidated final results of the Group for FY2025 may be subject to adjustment following the review by the Board and the auditors of the Company.

The Board expects that the announcement of the consolidated final results of the Group for FY2025 will be published before the end of March 2026 in full compliance with the requirements under the Listing Rules.

Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Green Fresh Biotechnology Company Limited
CHAN Kam Chung
Chairman and Chief Executive Officer

Hong Kong, 6 March 2026

As of the date of this announcement, the executive Directors are Mr. CHAN Kam Chung (Chairman and Chief Executive Officer), Mr. GUO Dongxu, Mr. CHAN Shui Yip, Mr. SHE Xiaoying and Ms. CHEN Yi and the independent non-executive Directors are Mr. HO Kwai Ching, Mark, Mr. NG Man Kung and Mr. HU Guohua.